Key result
Epstein-Barr virus is present in ~58% of Burkitt lymphoma patients worldwide.
Why the study?
Estimating the prevalence of Epstein-Barr virus may help predict whether a population is at high risk of increased Burkitt lymphoma cases.
What is the prevalence of Epstein-Barr virus in patients with Burkitt lymphoma?
Meta-Analysis (n=4,837)
Yes
What is the prevalence of Epstein-Barr virus in patients with Burkitt lymphoma?
EBV is present in more than half of patients with Burkitt lymphoma, suggesting EBV testing could assist in predicting and assessing clinical disease status.
Answers are grounded in this paper and cite their sources.
Supports EBV testing to assess Burkitt lymphoma status; extends prior estimates with worldwide pooled data.
Burkitt lymphoma (BL) is a form of B-cell malignancy that progresses aggressively and is most often seen in children. While Epstein–Barr virus (EBV) is a double-stranded DNA virus that has been linked to a variety of cancers, it can transform B lymphocytes into immortalized cells, as shown in BL. Therefore, the estimated prevalence of EBV in a population may assist in the prediction of whether this population has a high risk of increased BL cases. This systematic review and meta-analysis aimed to estimate the prevalence of Epstein–Barr virus in patients with Burkitt lymphoma. Using the appropriate keywords, four electronic databases were searched. The quality of the included studies was assessed using the Joanna Briggs Institute’s critical appraisal tool. The results were reported as percentages with a 95% confidence interval using a random-effects model (CI). PROSPERO was used to register the protocol (CRD42022372293), and 135 studies were included. The prevalence of Epstein–Barr virus in patients with Burkitt lymphoma was 57.5% (95% CI: 51.5 to 63.4, n = 4837). The sensitivity analyses demonstrated consistent results, and 65.2% of studies were of high quality. Egger’s test revealed that there was a significant publication bias. EBV was found in a significantly high proportion of BL patients (more than 50% of BL patients). This study recommends EBV testing as an alternative for predictions and the assessment of the clinical disease status of BL.
No takes yet. Share an insight, caveat, or question.
Al‐Khreisat et al. (2023) conducted a meta-analysis in Burkitt lymphoma (n=4,837). Epstein-Barr virus was evaluated on Prevalence of Epstein-Barr virus (95% CI 51.5 to 63.4). Epstein-Barr virus was present in 57.5% of patients with Burkitt lymphoma worldwide.
Synapse has enriched 10 related papers. Consider them for comparative context: